Importance of BRAF Testing Grows as Options Expand in MelanomaDecember 28th 2015
As clinical experience grows with new agents, combinations, and sequences of therapy, the use of molecular profiling in metastatic melanoma is likely to become an essential means of choosing among treatment options.
Debating the Merits of New Therapeutic Stars in NSCLCOctober 29th 2015
Between immunotherapies and targeted therapies-both of which certainly offer bold new opportunities for disease control over cytotoxic therapies-which treatment modality do oncologists think has had the greatest overall impact on NSCLC treatment?
FDA Grants Rindopepimut Breakthrough Designation for EGFRvIII-Positive GlioblastomaFebruary 23rd 2015
Rindopepimut (Rintega) has gained a Breakthrough Therapy Designation from the FDA to treat adult patients with glioblastoma multiforme that test positive for the epidermal growth factor receptor variant.
Two Phase III Trials Find Rolapitant Effective, Well-Tolerated for Preventing CINVJune 28th 2014
A single oral dose of rolapitant was found to be effective, safe, and long-lasting for the prevention of CINV in patients whose cancer was being treated with either highly or moderately emetogenic chemotherapy.
Single-Dose of Dexamethasone Adequate With Palonosetron for Controlling CINVJune 28th 2014
Palonosetron administered with a single-dose of dexamethasone adequately controlled nausea and vomiting associated with non-anthracycline-based moderately emetogenic chemotherapy when compared with a longer duration of dexamethasone.
Aprepitant- and Metoclopramide-Based Regimens Demonstrate Similar Efficacy in Preventing Delayed Cisplatin-Induced EmesisJune 27th 2014
For the prevention of nausea and vomiting after the first day of cisplatin-based chemotherapy, both aprepitant and metoclopramide when used in combination with dexamethasone were found to be similarly effective.